Fibromyalgia

Implantable Medical Devices Market to grow by USD 51.1 billion from 2022-2027 | North America to account for 45% of market growth - Technavio

Retrieved on: 
Tuesday, September 26, 2023
LivaNova, Prevalence, Osteoporosis, Abbott Laboratories, Tetraplegia, Segment, National Center for Spinal Disorders, SE, Stryker Corporation, Rheumatoid arthritis, Dental implant, Gout, Hip, Zimmer Biomet, Lupus, Cardinal Health, USD, CDC, Medial knee injuries, Boston Scientific, Circulatory system, Growth, Assurant, Orthopedic surgery, Trauma, Clifton Springs Hospital & Clinic, Arthritis, Hospital, NuVasive, Research, Arthropathy, Knee, Laboratory, AbbVie, Ophthalmic, ROW, Korea Disease Control and Prevention Agency, Fibromyalgia, Medtronic, Medical device, Retail, Application, Geography

NEW YORK, Sept. 25, 2023 /PRNewswire/ -- The implantable medical devices market size is expected to grow by USD 51.1 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Sept. 25, 2023 /PRNewswire/ -- The implantable medical devices market size is expected to grow by USD 51.1 billion from 2022 to 2027.
  • Hence, such factors drive the growth of the implantable medical devices market during the forecast period.
  • Detailed information on factors that will drive the growth of the implantable medical devices market between 2022 and 2027.
  • Growth of the implantable medical devices market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of implantable medical devices market vendors.

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

Retrieved on: 
Monday, September 18, 2023
Drug discovery, Celecoxib, Polaris Sales Agreement, Disorder, Long COVID, Patent, Capital, Fibromyalgia, Conditional sentence, Therapy, Valaciclovir, Food, Fatigue, Pharmaceutical industry

ATLANTA, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID, today announced that it provided notice of termination of the Capital on Demand™ Sales Agreement entered into between the Company and JonesTrading Institutional Services LLC on July 14, 2023 (the “Sales Agreement”).

Key Points: 
  • ATLANTA, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID, today announced that it provided notice of termination of the Capital on Demand™ Sales Agreement entered into between the Company and JonesTrading Institutional Services LLC on July 14, 2023 (the “Sales Agreement”).
  • The Company has initiated the 10-day termination process under the Sales Agreement, with the official termination taking effect on September 28, 2023.
  • The Company will make no sales under the Sales Agreement during this period.
  • Prosecuting a patent application covering the treatment of Long-COVID and Alzheimer’s disease with combination antiviral formulations.

The Rheumatology Research Foundation Introduces “The Rheumatology Lab”

Retrieved on: 
Monday, September 18, 2023
Data Management, Nursing, Seniors, Other Science, Technology, FDA, Physical Therapy, Research, Managed Care, Other Health, Consumer, Pharmaceutical, Hospitals, Genetics, Fitness & Nutrition, Clinical Trials, Biotechnology, Alternative Medicine, Software, Health, Science, Gout, Arthritis, Rheumatology Research Foundation, Hope, Rheumatology, Lupus, MD, Patient, Fibromyalgia, John Holer, Caregiver, Rheumatism, Rheumatoid arthritis, Pharmaceutical industry

The Rheumatology Research Foundation is pleased to announce its latest outreach initiative, the Rheumatology Lab .

Key Points: 
  • The Rheumatology Research Foundation is pleased to announce its latest outreach initiative, the Rheumatology Lab .
  • Through this new online resource, the Foundation can highlight Foundation-funded research, share new findings and perspectives, and amplify the voices of those affected by rheumatic disease.
  • “The time is now to increase awareness while providing all-inclusive online resources where both patients and clinicians access insights into rheumatic disease research,” said V. Michael Holers, MD, Rheumatology Research Foundation President.
  • Our mission is to advance research and training to improve the health of patients living with rheumatic disease, and that’s why our funding priorities are a main focal point of the Rheumatology Research Foundation’s overall mission.”

Martin Searle Solicitors run their annual October 2023 campaign "Disability Matters" to stamp out Disability Discrimination in the Workplace

Retrieved on: 
Monday, September 18, 2023
Organic, Office for National Statistics, Employment, Partnership, Institute of Employability Professionals, Workplace, Commons, Health, Labour law, Canadian House of Commons Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities, Multimedia, COVID, Citizens Advice, Government, FAQ, Disability, Chronic fatigue syndrome, HR, ONS, Equality Act, Equality Act 2010, House, Police Citizens Youth Club, Pharmaceutical industry, Insurance, Health insurance, Coronavirus, Fibromyalgia

BRIGHTON, United Kingdom, Sept. 18, 2023 /PRNewswire-PRWeb/ -- This October, Martin Searle Solicitors' Employment Law team are launching 'Disability Matters', their annual campaign to stamp out disability discrimination at work. This campaign will concentrate on Chronic Fatigue Syndrome and other medical conditions such as Long Covid and Fibromyalgia, which can produce similar symptoms.

Key Points: 
  • This October, Martin Searle Solicitors' Employment Law team are launching 'Disability Matters', their annual campaign to stamp out disability discrimination at work.
  • BRIGHTON, United Kingdom, Sept. 18, 2023 /PRNewswire-PRWeb/ -- This October, Martin Searle Solicitors ' Employment Law team are launching 'Disability Matters', their annual campaign to stamp out disability discrimination at work.
  • - Fiona Martin, Director and Head of Employment Law
    Despite disability discrimination in the workplace being outlawed we are dealing with increasing numbers of employees experiencing discrimination.
  • Martin Searle Solicitors are providing a free 30 minute confidential advice line for employers and employees on disability rights and employer duties throughout October 2023.

Tonix Pharmaceuticals Announces Poster Presentation Involving TNX-1700 in Preclinical Colorectal Cancer Models at the Seventh International Cancer Immunotherapy Conference 2023

Retrieved on: 
Thursday, September 14, 2023
Long COVID, Psychiatry, Prader–Willi syndrome, Headache, Central nervous system, Sumatriptan, Obesity, Failure, Therapy, Binge eating disorder, COVID-19, Infection, Cancer, Smallpox, PPAR, SL, Disease, Research, Risk, Upsher-Smith Laboratories, CNS, Autoimmunity, Government, Pain, Breakthrough therapy, Hydrogen chloride, Orphan drug, MDD, DSM-IV codes, Annual report, Gustav Neuring, Neurology, Social anxiety disorder, Fibromyalgia, Security (finance), FDA, Migraine, CD40L, Long, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults.

Key Points: 
  • Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults.
  • Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates.
  • Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.
  • Enrollment in a Phase 2 proof-of-concept study has been completed, and topline results were reported in the third quarter of 2023.

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

Retrieved on: 
Tuesday, September 12, 2023
Fibromyalgia, Conditional sentence, Therapy, Pharmaceutical industry

ATLANTA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the SHARE™️ Series Monday Management Update for investors on Monday, September 18, 2023, at 11:00 am ET.

Key Points: 
  • ATLANTA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the SHARE™️ Series Monday Management Update for investors on Monday, September 18, 2023, at 11:00 am ET.
  • This virtual event combines a brief corporate overview with a moderated fireside chat and provides access to individual and institutional investors who will have the opportunity to submit questions during the live session.
  • A link to the live and archived webcast may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations .

Tonix Pharmaceuticals Announces Topline Results from Phase 2 PREVAIL Proof-of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID

Retrieved on: 
Tuesday, September 5, 2023
PROMIS, Tonix Pharmaceuticals, AE, Fatigue, Week, Disability, COVID-19, National Institutes of Health, SL, COVID, PGIC, Tablet, Patient, Fibromyalgia, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NIH, Food, Pharmaceutical industry, Long COVID

CHATHAM, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced topline results from the Phase 2 proof-of-concept PREVAIL study of TNX-102 SL 5.6 mg for the management of fibromyalgia-type Long COVID. TNX-102 SL treatment showed a robust effect size (ES) in improving fatigue and showed consistent activity trending to improvements across the secondary endpoints of sleep quality, cognitive function, disability and patient global impression of change (PGIC). TNX-102 SL trended towards improvement but did not achieve the pre-specified primary endpoint of improving Long COVID pain intensity scores at Week 14. The proposed mechanism of TNX-102 SL is improving sleep quality, which NIH recently announced is a target of future RECOVER clinical trials in Long COVID, a National Institute of Health (NIH) research program designed to understand, treat, and prevent long COVID.1,2 There is currently no approved drug for the treatment of Long COVID.

Key Points: 
  • TNX-102 SL trended towards improvement but did not achieve the pre-specified primary endpoint of improving Long COVID pain intensity scores at Week 14.
  • PREVAIL was a randomized, double-blind, placebo-controlled, multi-site proof-of-concept study of 63 patients with laboratory-documented COVID-19 illness preceding Long COVID.
  • PREVAIL was designed and conducted to guide the design of registrational studies of TNX-102 SL in fibromyalgia-type Long COVID.
  • TNX-102 SL was generally well tolerated with an adverse event (AE) profile comparable to prior studies with TNX-102 SL.

CENTER FOR PAIN MANAGEMENT WELCOMES DR. JOSHUA WELLINGTON, MD.

Retrieved on: 
Friday, September 1, 2023
Spaulding Rehabilitation Hospital, Boston Children's Hospital, Intrathecal pump, Piriformis syndrome, Beth Israel Deaconess Medical Center, Neck pain, Arthralgia, Interventional pain management, Arthritis, Medical college, Therapy, Twilight anesthesia, ITP, Cancer, North American Neuromodulation Society, American Academy, CRPS, Medicine, MS, Harvard Medical School, Public key certificate, Back pain, Rehabilitation, Medical director, Patient, Physician, Practitioner, Physical medicine and rehabilitation, Fibromyalgia, Hospital, Health, NANS, Chronic pain, Headache, Society, Targeted drug delivery, Injury, Nursing, Dentistry, Pain management, MD

INDIANAPOLIS, Sept. 1, 2023 /PRNewswire/ -- Center for Pain Management, together with American Pain Consortium, a leading network of interventional pain practices, is pleased to announce that Joshua Wellington, MD, MS, has joined their practice and will be seeing patients starting September 5, 2023.

Key Points: 
  • INDIANAPOLIS, Sept. 1, 2023 /PRNewswire/ -- Center for Pain Management, together with American Pain Consortium, a leading network of interventional pain practices, is pleased to announce that Joshua Wellington, MD, MS, has joined their practice and will be seeing patients starting September 5, 2023.
  • He will be joining Center for Pain Management to lead the Targeted Drug Delivery program, which will expand patient access to quality care for Intrathecal Pump (ITP) implants.
  • Center for Pain Management, supported by American Pain Consortium, proudly serves Indiana with 7 clinics and 4 Ambulatory Surgery Centers statewide and has been treating a wide range of acute and chronic pain conditions since 1993.
  • The physicians specialize in back pain, neck pain, headache, and joint pain resulting from injuries, arthritis, cancer, fibromyalgia, failed back surgery, Complex Regional Pain Syndromes (CRPS), and other disorders.

MediPharm Labs Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients

Retrieved on: 
Thursday, August 31, 2023
Depression, Education, Placebo, FSE, Insomnia, American Journal, Patient, CBD, Cannabis, TSX, Chronic pain, Fatigue, Medical device, Nursing, Pharmaceutical industry, Anxiety, Fibromyalgia

Between baseline and follow-up appointments, 75% of patients saw a significant decrease in their self-reported illness severity and the study reported reductions in depression and anxiety scores.

Key Points: 
  • Between baseline and follow-up appointments, 75% of patients saw a significant decrease in their self-reported illness severity and the study reported reductions in depression and anxiety scores.
  • The study data shows that medical cannabis may play an effective role in the management of fibromyalgia and associated symptoms of depression and anxiety.
  • Harvest Medicine Inc. ("Harvest Medicine" or "HMED") includes a medical clinic network, and is a wholly owned subsidiary of MediPharm Labs.
  • Anxiety scores were improved in 22% of those patients reporting mild-moderate severity, and in 48% of patients reporting severe anxiety.

Tonix Pharmaceuticals to Present at the August Virtual Investor Summit

Retrieved on: 
Thursday, August 17, 2023
Long COVID, Psychiatry, Prader–Willi syndrome, Headache, Central nervous system, Sumatriptan, Obesity, Failure, Therapy, IR, Binge eating disorder, COVID-19, Infection, Cancer, Smallpox, PPAR, SL, Disease, Research, Risk, Upsher-Smith Laboratories, CNS, Autoimmunity, Government, Pain, Breakthrough therapy, Hydrogen chloride, Orphan drug, MDD, DSM-IV codes, Annual report, Neurology, Social anxiety disorder, Fibromyalgia, Security (finance), FDA, Migraine, CD40L, Long, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

CHATHAM, N.J., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals, will present at the August 2023 Virtual Investor Summit on Thursday, August 24, 2023, at 10:00 a.m.

Key Points: 
  • CHATHAM, N.J., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals, will present at the August 2023 Virtual Investor Summit on Thursday, August 24, 2023, at 10:00 a.m.
  • Investors interested in arranging a meeting with the Company’s management during the conference should contact the Investor Summit conference coordinator.
  • A webcast of the presentation can be found here and will be available under the IR Events tab of the Tonix website at www.tonixpharma.com .
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.